Literature DB >> 10147287

Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach.

D P Nicolau1, R Quintiliani.   

Abstract

The use of pharmacodynamic properties when formulating antibacterial administration guidelines can maximise the potential for efficacy while minimising the risk of toxicity. Aminoglycosides and quinolones demonstrate concentration-dependent bactericidal killing, which is maximised when their concentrations appreciably exceed their minimum inhibitory concentration (MIC) for an organism. beta-Lactams demonstrate time-dependent or concentration-independent bactericidal killing, which is maximised when the time that concentrations exceed the MIC is prolonged, regardless of the absolute levels attained. Methods of prolonging the time beta-lactam concentrations exceed the MIC include the following: interfering with excretion (e.g. probenecid); decreasing the dosage interval; increasing the dose; infusing continuously rather than by bolus; and choosing an agent with a prolonged elimination half-life. The optimal duration for exceeding the MIC varies with the infecting organism, site of infection, inoculum effect, and the immunocompetence of the host. Integration of the microbiological activity and pharmacokinetic properties enables estimation of the time that serum concentrations of various cephalosporins will exceed the MIC of a given organism, consequently allowing estimation of the relative potential for clinical success. Cefixime, a third generation oral cephalosporin with a long plasma elimination half-life, allowing once-daily administration, achieves serum concentrations that exceed the MIC of Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, and Group A streptococci for greater than 90% of the dosage interval, and the MIC of Streptococcus pneumoniae for 50 to 90% of the dosage interval.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10147287     DOI: 10.2165/00019053-199400052-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

1.  Once-daily aminoglycosides.

Authors:  D Nicolau; R Quintiliani; C H Nightingale
Journal:  Conn Med       Date:  1992-10

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Comparison of gentamicin dosing regimens using an in-vitro model.

Authors:  E J Begg; B A Peddie; S T Chambers; D R Boswell
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

Review 4.  Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design.

Authors:  S C Ebert; W A Craig
Journal:  Infect Control Hosp Epidemiol       Date:  1990-06       Impact factor: 3.254

5.  Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

6.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 7.  Mechanism of bactericidal action of aminoglycosides.

Authors:  B D Davis
Journal:  Microbiol Rev       Date:  1987-09

8.  Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections.

Authors:  P J de Vries; R P Verkooyen; P Leguit; H A Verbrugh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

9.  Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors: 
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

10.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

View more
  4 in total

1.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

2.  Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

Authors:  D P Nicolau; C H Nightingale; M A Banevicius; Q Fu; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Effects of renal function on the pharmacokinetics and pharmacodynamics of prophylactic cefazolin in cardiothoracic surgery.

Authors:  T Kosaka; K Hosokawa; N Shime; F Taniguchi; T Kokufu; S Hashimoto; H Fujiwara; H Yaku; N Sugioka; K Okada; N Fujita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-20       Impact factor: 3.267

4.  Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.

Authors:  Jun Shi; Marc Pfister; Stephen G Jenkins; Sunny Chapel; Jeffrey S Barrett; Ruedi E Port; Dan Howard
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.